The usefulness of metabolic volume in diagnosing malignant tumor in FDG-PET/CT

Japanese Journal of Clinical Radiology

Volumn 53, Issue 8, 2008, Pages 997-1003

  Kiyohara, Shogo ^a   Nagamachi, S ^a   Wakamatsu, H ^a   Fujita, S ^a   Futami, S ^a   Tamura, S ^a  

^a UNIVERSITY OF MIYAZAKI   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE;

ARTICLE; CANCER RECURRENCE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC VALUE; LARGE CELL LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; POSITRON EMISSION TOMOGRAPHY; TUMOR VOLUME;

EID: 49749120588     PISSN: 00099252     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Saga T et al : Positron emission tomography : basic principle and radionuclides/probes for metabolic/functional analysis. Rinsho Byori 55 : 630-638, 2007
2. Kubota K : From tumor biology to clinical Pet : a review of positron emission tomography (PET) in oncology. Ann Nucl Med 15 : 471-486, 2001
3. Vesselle H et al : Fluorodeoxyglucose uptake of primary non-small cell lung cancer at positron emission tomography : new contrary data on prognostic role. Clin Cancer Res 13 : 3255-3263, 2007
4. 18F FDG PET-CT imaging. Radiat Oncol 2 : 18, 2007
5. 18F-FDG PET and contrast-enhanced CT scan in the assessment of residual liver metastasis from colorectal cancer following adjuvant chemotherapy. Nucl Med Rev Cent East Eur 10 : 12-15, 2007
6. Sun L et al : Positron emission tomography/computer tomography : challenge to conventional imaging modalities in evaluating primary and metastatic liver malignancies. World J Gastroenterol 13 : 2775-2783, 2007
7. Hayasaka K et al : Metastasis of the gastrointestinal tract : FDG-PET imaging. Ann Nucl Med 21 : 361-365, 2007
8. Yao M et al : Pathology and FDG PET correlation of residual lymph nodes in head and neck cancer after radiation treatment. Am J Clin Oncol 30 : 264-270, 2007
9. Buchmann I et al : FDG-PET in the initial staging of squamous cell oesophageal carcinoma. Nuklearmedizin 45 : 235-241, 2006
10. 18F-FDG PET/CT for patients with suspected recurrence from squamous cell carcinoma of the esophagus. J Nucl Med 48 : 1251-1258, 2007
11. Bang S et al : The clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the differential diagnosis, staging, and response evaluation after concurrent chemoradiotherapy for pancreatic cancer. J Clin Gastroenterol 40 : 1923-1929, 2006
12. MacManus MP et al : Overview of early response assessment in lymphoma with FDG-PET. Cancer Imaging 7 : 10-18, 2007
13. Seam P et al : The role of FDG-PET scans in patients with lymphoma. Blood. 110 : 3507-3516, 2007
14. Podoloff DA, Macapinlac HA : PET and PET/CT in Management of the Lymphomas. Radiol Clin North Am 45 : 689-696, 2007
15. Bar-Shalom R : Normal and abnormal patterns of (18) F-Fluorodeoxyglucose PET/CT in lymphoma. Radiol Clin North Am 45 : 677-688, 2007
16. Basu S et al : Detection of unsuspected metachronous second primary malignancy giving rise to supposed "non-iodine avid metastasis" in differentiated thyroid carcinoma. Clin Nucl Med 32 : 655-658, 2007
17. Koga S et al : FDG-PET (positron emission tomography) in the detection of primary breast cancer and lymph node involvement. Nippon Rinsho 65 (suppl 6) : 379-384, 2007
18. 18F fluorodeoxyglucose-positron emission tomography in breast cancer. Radiol Clin North Am 45 : 659-667, 2007
19. 18F-FDG-PET in breast cancer imaging. Nippon Rinsho 65 (suppl 6) : 373-378, 2007
20. 18F fluorodeoxyglucose is a sensitive predictive biomarker for cervical cancer treatment response and survival. Cancer 110 : 1738-1744, 2007
21. Japanese source
22. 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma : SUV-based assessment versus visual analysis. J Nucl Med 48 : 1626-1632, 2007
23. 18F]-fluoro-2-deoxy-D-glucose in rodents with mammary carcinoma. Radiology 183 : 643-647, 1992
24. Kubota K et al : Advantage of delayed imaging of whole-body FDG-PET for tumor detection. Eur J Nucl Med 28 : 696-703, 2001
25. Basu S, Alavi A : Partial volume correction of standardized uptake values and the dual time point in FDG-PET imaging : should these be routinely employed in assessing patients with cancer? Eur J Nucl Med Mol Imaging 34 : 1527-1529, 2007
26. Lartizien C et al : Optimization of injected dose based on noise equivalent count rate for 2- and 3-dimentional whole-body PET. J Nucl Med 43 : 1268-1278, 2002